NEW YORK (GenomeWeb News) — Arcxis Biotechnologies has received a $1 million Phase II award from the US Department of Homeland Security to continue developing its BioPhalanx instrument, a portable, rapid-detection bio-threat analyzer, the company said Tuesday. 
The Pleasanton, Calif.-based company said the funding comes after it demonstrated a genomic probe assay for viruses causing anthrax and plague that does not report false positive results.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.